Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies ...
Despite near-term headwinds, RxSight has long-term upside from the Alcon royalty partnership, stronger margins and discounted ...
Alcon (SWX:ALC) shares are in focus after the company agreed a non exclusive collaboration with RxSight to co develop ...
RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the ...
GENEVA--(BUSINESS WIRE)--Alcon, the global leader in eye care, today announced plans to launch the newest addition to its robust contact lens portfolio – PRECISION1 ® daily disposable, silicone ...
“Alcon is proud to be the title sponsor of SECO 2020 and welcomes the opportunity to connect with Eye Care Professionals (ECPs) while providing hands-on access to our latest, innovative eye care ...
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Alcon Inc. (NYSE:ALC) is one of the best ...
PRECISION1 is the first mainstream daily disposable contact lens to use SMARTSURFACE Technology to deliver lasting visual performance and comfort1 New clinical data show five times more contact lens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results